Stock Analiz

ImmunityBio, Inc. (IBRX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

ImmunityBio’s revenue went from $44000 in fiscal 2016 to $113M in fiscal 2025, growth of about 139.3% a year.

Net income in fiscal 2025 was -$351M, a net margin of -310.2%; the best year in this period was 2018 with -$96M.

Over the twelve months to September 30, 2026, revenue was $183M and net income -$1.1B.

Free cash flow was -$309M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 1022% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $44000162017: $45000172018: $47000182019: $2M192020: $605000202021: $934000212022: $240000222023: $622000232024: $15M242025: $113M25$113M
Net income
2016: -$121M162017: -$96M172018: -$96M182019: -$158M192020: -$222M202021: -$347M212022: -$417M222023: -$583M232024: -$414M242025: -$351M25-$351M
Free cash flow
2016: -$45M162017: -$84M172018: -$76M182019: -$156M192020: -$173M202021: -$308M212022: -$416M222023: -$397M232024: -$398M242025: -$309M25-$309M
EPS (diluted)
2016: $-1.47162017: $-1.20172018: $-1.22182019: $-0.43192020: $-0.59202021: $-0.89212022: $-1.04222023: $-1.15232024: $-0.62242025: $-0.3825$-0.38

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$183M$113M$15M$622000$240000$934000$605000$2M$47000$45000$44000
Gross profit$180M$113M$15M$622000$240000——————
Operating income-$274M-$256M-$344M-$362M-$351M-$330M-$221M-$156M-$98M-$99M-$124M
Net income-$1.1B-$351M-$414M-$583M-$417M-$347M-$222M-$158M-$96M-$96M-$121M
EPS (diluted)$-1.08$-0.38$-0.62$-1.15$-1.04$-0.89$-0.59$-0.43$-1.22$-1.20$-1.47
R&D——$190M$232M$248M$196M$140M$112M$56M$42M$29M
Revenue growth—+668.3%+2270.6%+159.2%−74.3%+54.4%−72.5%+4585.1%+4.4%+2.3%−81.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$288M-$305M-$391M-$367M-$338M-$274M-$172M-$152M-$63M-$49M-$39M
Capital spending-$9M-$4M-$7M-$31M-$78M-$34M-$2M-$4M-$13M-$35M-$7M
Free cash flow-$297M-$309M-$398M-$397M-$416M-$308M-$173M-$156M-$76M-$84M-$45M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks—————$0$0$3M$228000$15M$16M
Stock-based pay$34M$37M$34M$49M$40M$57M$2M$3M$23M$37M$74M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$243M$150M$266M$107M$317M$96M$112M$74M$128M$199M
Debt—$367M$328M$201M$483M$40M$15M$14M———
Equity—-$500M-$489M-$587M-$447M-$242M-$120M$121M$146M$219M$293M
Total assets—$502M$383M$504M$362M$469M$221M$143M$182M$250M$317M
Shares (diluted)1.06B920M700M509M400M389M377M366M79M81M82M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin98.8%99.3%100.0%100.0%100.0%——————
Operating margin-150.2%-226.0%-2334.2%-58239.5%-146400.0%-35361.9%-36509.1%-7095.9%-209300.0%-220300.0%-283000.0%
Net margin-607.8%-310.2%-2804.8%-93761.4%-173600.0%-37129.6%-36669.6%-7165.2%-204700.0%-214300.0%-274600.0%
FCF margin-162.5%-272.6%-2700.1%-63881.2%-173200.0%-32974.5%-28660.0%-7102.5%-162700.0%-185800.0%-102600.0%
ROIC————-789.0%——-115.9%-67.0%-45.1%-42.2%
ROE—70.2%84.6%99.4%93.1%143.2%185.2%-130.7%-65.9%-44.1%-41.2%

Frequently asked questions

What is ImmunityBio’s annual revenue?

$113M in fiscal 2025 and $183M over the twelve months to September 30, 2026.

How much profit does ImmunityBio make?

Net income was -$351M in fiscal 2025 (net margin -310.2%).

Is ImmunityBio’s revenue growing?

Yes: revenue rose 668.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.